Delving into the Latest Updates on Tolperisone Hydrochloride with Synapse

Tolperisone is a centrally acting muscle relaxant that has been used for the treatment of post-stroke spasticity and low back pain. Recently, the safety of tolperisone pharmaceutical products has been reassessed due to growing concerns over allergic adverse events. Reactive degradants of tolperisone may be responsible for these hypersensitivity reactions. By forming adducts with proteins, they may act as haptens that could evoke allergic reactions. The objective of this study was to examine the presence of these degradants in tolperisone pharmaceutical products and to assess their reactivity to elucidate their possible role in the pro-allergic effect of tolperisone. For this purpose, capillary electrophoresis UV detection (CE-UV) method was developed and validated for the quantification of degradants. A dual cyclodextrin system was applied to achieve the appropriate migration order enabling the analysis of 2-methyl-1-(4-methylphenyl)prop-2-en-1-one (MMP) and 1-(4-methylphenyl)propan-1-one (MMPO) in the presence of high concentrations of tolperisone. MMP was identified as the main degradant in forced degradation tests of the active pharmaceutical ingredient. Differences in MMP content of tolperisone products by different manufacturers have also been found, highlighting the role of formulation in their stability. High reactivity of MMP was demonstrated as rapid and almost complete adduct formation with cysteine was found. This degradant thus might be responsible for the allergic adverse effects of tolperisone even when it is present in trace amounts in tablets by readily reacting with proteins in vivo.

01 Oct 2024·Science of The Total Environment

Metabolomic study on ostracods exposed to environmentally relevant concentrations of five pharmaceuticals selected via a novel approach

Article

Author: Chojnacka, Justyna ; Giebułtowicz, Joanna ; Michorowska, Sylwia ; Marek, Dominik ; Kucharski, Dawid ; Nałęcz-Jawecki, Grzegorz

Pharmaceuticals (PhACs) are increasingly detected in aquatic ecosystems, yet their effects on biota remain largely unknown. The environmentally relevant concentrations of many PhACs may not result in individual-level responses, like mortality or growth inhibition, traditional toxicity endpoints. However, this doesn't imply the absence of negative effects on biota. Metabolomics offers a more sensitive approach, detecting responses at molecular and cellular levels and providing mechanistic understanding of adverse effects. We evaluated bioaccumulation and metabolic alterations in a benthic ostracod, Heterocypris incongruens, exposed to a mixture of five PhACs (carbamazepine, tiapride, tolperisone, propranolol and amlodipine) at environmentally relevant concentrations for 7 days using liquid chromatography coupled with mass spectrometry. The selection of PhACs was based, among other factors, on risk quotient values determined using toxicological data available in the literature and concentrations of PhACs quantified in our previous research in the sediments of the Odra River estuary. This represents a novel approach to PhACs selection for metabolomic studies that considers strictly quantitative data. Amlodipine and tolperisone exhibited the highest bioaccumulation. Significant impacts were observed in Alanine, aspartate and glutamate metabolism, Starch and sucrose metabolism, Arginine biosynthesis, Histidine metabolism, Tryptophan metabolism, Glycerophospholipid metabolism, and Glutathione metabolism pathways. Most of the below-individual-level responses were likely nonspecific and related to dysregulation in energy metabolism and oxidative stress response. Additionally, some pharmaceutical-specific responses were also observed. Therefore, untargeted metabolomics can be used to detect metabolic changes resulting from environmentally relevant concentrations of PhACs in aquatic ecosystems and to understand their underlying mechanism.

01 May 2024·Biomedicine & Pharmacotherapy

Tolperisone hydrochloride improves motor functions in Parkinson’s disease via MMP-9 inhibition and by downregulating p38 MAPK and ERK1/2 signaling cascade

Article

Author: Hassan, Tazree ; Chowdhury, Fowzia Afsana ; Uddin, Kabir M ; Hossain, Md Mainul ; Mallick, Anup ; Mostafa, Irona ; Rahman, Mahbubur ; Sharmin, Ayesha ; Zaman, Bushra ; Bosu, Tory ; Chowdhury, Humayra Noor ; Islam, Mm Shanjid ; Esha, Nusrat Jahan Ikbal ; Ahmed, Shamim

The mitogen-activated protein kinase (MAPK) signaling pathway, particularly the p38 MAPK and ERK1/2, has been implicated in the pathogenesis of Parkinson's disease (PD). Recent studies have shown that MAPK signaling pathway can influence the expression of matrix metalloproteinase 9 (MMP-9), known for its involvement in various physiological and pathological processes, including neurodegenerative diseases. This study explores the modulation of MMP-9 expression via the MAPK/ERK signaling cascade and its potential therapeutic implications in the context of PD-associated motor dysfunction. Here, tolperisone hydrochloride (TL), a muscle relaxant that blocks voltage-gated sodium and calcium channels, was used as a treatment to observe its effect on MAPK signaling and MMP-9 expression. Rotenone (RT) exposure in mice resulted in a significant reduction in substantia nigra and primary motor cortex neurons, which were further evidenced by impairments in motor function. When TL was administered, neuron count was restored (89.0 ± 4.78 vs 117.0 ± 4.46/mm²), and most of the motor dysfunction was alleviated. Mechanistically, TL reduced the protein expression of phospho-p38MAPK (1.06 fold vs 1.00 fold) and phospho-ERK1/2 (1.16 fold vs 1.02 fold), leading to the inhibition of MAPK signaling, as well as reduced MMP-9 concentrations (2.76 ± 0.10 vs 1.94 ± 0.10 ng/mL) in the process of rescuing RT-induced neuronal cell death and motor dysfunction. Computational analysis further revealed TL's potential inhibitory properties against MMP-9 along with N and L-type calcium channels. These findings shed light on TL's neuroprotective effects via MMP-9 inhibition and MAPK signaling downregulation, offering potential therapeutic avenues for PD-associated motor dysfunction.

2

News (Medical) associated with Tolperisone Hydrochloride

27 Mar 2023

·www.drugs.com

Comparative Effectiveness of Meds for Acute Low Back Pain Unclear

MONDAY, March 27, 2023 -- For patients with acute low back pain , the comparative effectiveness and safety of analgesic medications is unclear, according to a systematic review and meta-analysis published online March 22 in The BMJ . Michael A. Wewege, from the University of New South Wales in Sydney, and colleagues conducted a systematic review and network meta-analysis to assess the comparative effectiveness and safety of analgesic medicines for acute nonspecific low back pain. Data were reviewed from 98 randomized controlled trials (15,134 participants), which included 69 medicines and combinations. The researchers observed low or very low confidence in evidence for reduced pain intensity after treatment with tolperisone, aceclofenac plus tizanidine, pregabalin (mean differences, −26.1, −26.1, and −24.7, respectively), and 14 other medicines versus placebo. There was low or very low confidence seen for no difference between the effects of several of these medications. There was moderate to very low confidence noted for increased adverse events with tramadol, acetaminophen plus sustained-release tramadol, baclofen, and acetaminophen plus tramadol compared with placebo (risk ratio, 2.6, 2.4, 2.3, and 2.1, respectively). There was moderate-to-low confidence for these medicines increasing the risk for adverse events compared with other medicines. For secondary outcomes and a secondary analysis of medicine classes, moderate-to-low confidence was also noted. "Despite nearly 60 years of research involving more than 15,000 patients, high quality evidence to guide clinical decisions on analgesic medicines for acute nonspecific low back pain remains limited," the authors write. The Sydney Pharmacy School receives funding from GlaxoSmithKline for a postgraduate scholarship supporting a research student supervised by one of the authors. Abstract/Full Text Posted March 2023

Clinical Result

24 Nov 2021

·www.biospace.com

Neurana Pharmaceuticals to Present at Piper Sandler Healthcare Conference

SAN DIEGO, Nov. 24, 2021 /PRNewswire/ --Neurana Pharmaceuticals, Inc. a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, President and Chief Executive Officer, will present at the 33rd Annual Piper Sandler Healthcare Conference and participate in one-on-one meetings with investors. The conference takes place virtually November 29th – December 2nd. Presentations will be available for registered attendees via the Piper Sandler conference site. About Neurana Pharmaceuticals, Inc. Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana's lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. For additional information, please visit .

100 Deals associated with Tolperisone Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01507	Tolperisone Hydrochloride	M02AX06 M03BX04	DB06264

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Muscle Hypertonia	DE	SANOCHEMIA Pharmazeutika GmbH	16 Oct 2007
Cardiovascular Diseases	CN	Nanjing Baijingyu Pharmaceutical Co. Ltd.	01 Jan 1986
Muscle Spasticity	CH	Labatec Pharma SA	24 Aug 1966

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Pain	Phase 3	US	Neurana Pharmaceuticals, Inc.	15 Dec 2020
Back Pain	Phase 3	US	Neurana Pharmaceuticals, Inc.	15 Dec 2020
Lordosis	Phase 3	US	Neurana Pharmaceuticals, Inc.	15 Dec 2020
Spasm	Phase 3	US	Neurana Pharmaceuticals, Inc.	15 Dec 2020
Multiple Sclerosis	Phase 3	UA	Avigen, Inc.	01 Sep 2007
Multiple Sclerosis	Phase 3	RU	Avigen, Inc.	01 Sep 2007
Multiple Sclerosis	Phase 3	DE	Avigen, Inc.	01 Sep 2007
Multiple Sclerosis	Phase 3	RS	Avigen, Inc.	01 Sep 2007
Multiple Sclerosis	Phase 3	CZ	Avigen, Inc.	01 Sep 2007
Muscle Spasticity	Phase 3	CZ	SANOCHEMIA Pharmazeutika GmbH	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04671082 (RESUME-1, Biospace) Manual	Phase 3	Muscle Spasticity	1,004	Tolperisone Hydrochloride	(tlzdmqlmif) = failed to meet its primary endpoints khjrwkhmwg (zrxektwqop )	Positive	22 Mar 2022
NCT03802565 (STAR, CTgov)	Phase 2	Low Back Pain \| Spasm \| Acute Pain \| Muscle Cramp \| Lordosis	415	Tolperisone (Tolperisone 50 mg)	kxqfhdwcjr(ougezznswq) = fpqdthpuhp omnimfgriq (vwfavzzmrt, rddbkaylhm - kyaiswnpof) View more	-	10 Nov 2020
NCT03802565 (STAR, CTgov)	Phase 2		415	Tolperisone (Tolperisone 100 mg)	kxqfhdwcjr(ougezznswq) = ztwoljpfdq omnimfgriq (vwfavzzmrt, gnfvuxcvcg - dphcnmptkp) View more	-	10 Nov 2020